Alnylam Pharmaceuticals this week released new data from an ongoing phase I study of its liver cancer drug ALN-VSP02.

The drug comprises two siRNAs, one targeting vascular endothelial growth factor and one targeting kinesin spindle protein, both of which the firm said are critical for the growth and survival of cancer cells. It is formulated in a first-generation lipid nanoparticle developed by partner Tekmira Pharmaceuticals.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Cell this week: dynamics of protein profusion and localization, melanoma classification schemes, and more.

A company says it can generate likenesses of people based on their genetic profiles.

IBM's Watson is learning how to treat leukemia as a fellow at the MD Anderson Cancer Center, according to the Washington Post.

At her blog, Sally Rockey dives into National Institutes of Health funding data.